

Medical Policy Manual **Approved Rev: Do Not Implement until 12/3/24**

Temozolomide (Temodar®), temozolomide

IMPORTANT REMINDER

We develop Medical Policies to provide guidance to Members and Providers. This Medical Policy relates only to the services or supplies described in it. The existence of a Medical Policy is not an authorization, certification, explanation of benefits or a contract for the service (or supply) that is referenced in the Medical Policy. For a determination of the benefits that a Member is entitled to receive under his or her health plan, the Member's health plan must be reviewed. If there is a conflict between the medical policy and a health plan or government program (e.g., TennCare), the express terms of the health plan or government program will govern.

POLICY

I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

A. FDA-Approved Indications

1. Newly Diagnosed Glioblastoma
Temodar is indicated for the treatment of adult patients with newly diagnosed glioblastoma concomitantly with radiotherapy and then as maintenance treatment.
2. Anaplastic Astrocytoma
Temodar is indicated for the:
 - a. adjuvant treatment of adults with newly diagnosed anaplastic astrocytoma;
 - b. treatment of adults with refractory anaplastic astrocytoma.

B. Compendial Uses

1. Central nervous system (CNS) cancer
2. Ewing sarcoma
3. Neuroendocrine tumors of the pancreas, gastrointestinal tract, lung, and thymus
4. Well-differentiated grade 3 neuroendocrine tumors
5. Extrapulmonary Poorly differentiated (high grade) neuroendocrine carcinoma/large or small cell carcinoma
6. Pheochromocytoma/paraganglioma
7. Cutaneous melanoma
8. Uveal melanoma
9. Mycosis fungoides (MF)/Sézary syndrome (SS)
10. Small cell lung cancer
11. Soft tissue sarcoma
12. Uterine sarcoma
13. Neuroblastoma

All other indications are considered experimental/investigational and not medically necessary.

II. CRITERIA FOR INITIAL APPROVAL



Medical Policy Manual **Approved Rev: Do Not Implement until 12/3/24**

- A. Central nervous system (CNS) cancer**
Authorization of 12 months may be granted for treatment of CNS cancers.
- B. Ewing sarcoma**
Authorization of 12 months may be granted for treatment of Ewing sarcoma.
- C. Neuroendocrine tumors**
Authorization of 12 months may be granted for treatment of neuroendocrine tumors.
- D. Extrapulmonary Poorly differentiated (high-grade) neuroendocrine carcinoma/large or small cell carcinoma**
Authorization of 12 months may be granted for treatment of extrapulmonary poorly differentiated (high-grade) neuroendocrine carcinoma or large or small cell carcinoma.
- E. Pheochromocytoma/paraganglioma**
Authorization of 12 months may be granted for treatment of pheochromocytoma or paraganglioma.
- F. Cutaneous Melanoma**
Authorization of 12 months may be granted for treatment of cutaneous melanoma for metastatic or unresectable disease.
- G. Uveal Melanoma**
Authorization of 12 months may be granted for treatment of uveal melanoma for unresectable or metastatic disease.
- H. Mycosis fungoides (MF)/Sézary syndrome (SS)**
Authorization of 12 months may be granted for treatment of MF or SS.
- I. Small cell lung cancer (SCLC)**
Authorization of 12 months may be granted for treatment of SCLC.
- J. Soft tissue sarcoma (STS)**
Authorization of 12 months may be granted for treatment of STS.
- K. Uterine sarcoma**
Authorization of 12 months may be granted for treatment of uterine sarcoma.
- L. Neuroblastoma**
Authorization of 12 months may be granted for treatment of neuroblastoma when used in combination with irinotecan, dinutuximab, and sargramostim.

III. CONTINUATION OF THERAPY

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication listed in Section II when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.



Medical Policy Manual **Approved Rev: Do Not Implement until 12/3/24**

APPLICABLE TENNESSEE STATE MANDATE REQUIREMENTS

BlueCross BlueShield of Tennessee's Medical Policy complies with Tennessee Code Annotated Section 56-7-2352 regarding coverage of off-label indications of Food and Drug Administration (FDA) approved drugs when the off-label use is recognized in one of the statutorily recognized standard reference compendia or in the published peer-reviewed medical literature.

ADDITIONAL INFORMATION

For appropriate chemotherapy regimens, dosage information, contraindications, precautions, warnings, and monitoring information, please refer to one of the standard reference compendia (e.g., the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) published by the National Comprehensive Cancer Network®, Drugdex Evaluations of Micromedex Solutions at Truven Health, or The American Hospital Formulary Service Drug Information).

REFERENCES

1. Temodar [package insert]. Rahway, NJ: Merck & Co., Inc.; September 2023.
2. Temozolomide [package insert]. Durham, NC: Accord Healthcare, Inc.; October 2021.
3. The NCCN Drugs & Biologics Compendium® © 2024 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed July 9, 2024.

EFFECTIVE DATE 12/3/2024

ID_CHS